Find Reports
Select Report Type
Reimbursement Review
Displaying 276 - 300 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| immune globulin human and reco... | HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete | ST0695-000 | |||
| upadacitinib | Rinvoq | upadacitinib | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | SR0685-000 | |||
| cemiplimab | Libtayo | cemiplimab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0262-000 | |||
| Multiple myeloma | Multiple myeloma | Complete | PH0011-000 | ||||||
| Anaplastic Lymphoma Kinase Pos... | ALK-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | Complete | PH0009-000 | ||||||
| ospemifene | Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | SR0709-000 | |||
| selpercatinib | Retevmo | selpercatinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0261-000 | |||
| ripretinib | Qinlock | ripretinib | Gastrointestinal stromal tumours | Reimburse with clinical criteria and/or conditions | Complete | PC0265-000 | |||
| prasterone | Intrarosa | prasterone | Postmenopausal vulvovaginal atrophy | Reimburse with clinical criteria and/or conditions | Complete | SR0707-000 | |||
| Alpha1-proteinase inhibitor (H... | Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ST0702-000 | |||
| HER2-Positive Metastatic Breas... | HER2-Positive Metastatic Breast Cancer | Complete | PH0006-000 | ||||||
| fostamatinib | Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | SR0701-000 | |||
| bimekizumab | Bimzelx | bimekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0698-000 | |||
| Metastatic Urothelial Carcinom... | Metastatic Urothelial Carcinoma | Complete | PH0008-000 | ||||||
| pemigatinib | Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | PC0252-000 | |||
| lorlatinib | Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | PC0249-000 | |||
| colchicine | Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | SR0691-000 | |||
| somatrogon | Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | SR0683-000 | |||
| tralokinumab | Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | SR0689-000 | |||
| nivolumab | Opdivo | nivolumab | Gastric, gastroesophageal junction, or esophageal adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0259-000 | |||
| cemiplimab | Libtayo | cemiplimab | Basal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0260-000 | |||
| ravulizumab | Ultomiris | ravulizumab | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | SR0700-000 | |||
| estradiol and progesterone | Bijuva | estradiol and progesterone | Vasomotor symptoms associated with menopause | Reimburse with clinical criteria and/or conditions | Complete | SR0697-000 | |||
| trientine hydrochloride | Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | SR0696-000 | |||
| inclisiran | Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete | SR0681-000 |
Health Technology Review
Displaying 276 - 300 of 602
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 276 - 300 of 2138
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Advanced or metastatic gastric, gastroesophageal junction, or esophageal cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0051-000 | |||
| Attention-Deficit/Hyperactivity Disorder Medications for Adults | Health Technology Review | Rapid Review | Completed | RC1556-000 | |||
| Pharmaceutical Reviews Update — Issue 53 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Esophageal or Gastroesophageal Junction Cancer | Reimbursement Review | Provisional Funding Algorithm | Active | PH0061-000 | |||
| Overview of Systematic Reviews of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer with EGFR, ALK, ROS1, and RET Actionable Driver Mutations | Health Technology Review | Systematic Review | Completed | RE0050-000 | |||
| Utilization of Cancer Therapies for Advanced Non–Small Cell Lung Cancer With an Oncogenic Driver Mutation | Health Technology Review | Technology Review | Completed | HC0084-OS0008 | |||
| remdesivir | Reimbursement Review | Complete | SR0834-000 | ||||
| Benchmarking CT and MRI exams | Health Technology Review | In Progress | CM0016-000 | ||||
| Optimal Wait Times | Health Technology Review | In Progress | CM0014-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0344-000 | ||||
| Long-Acting Inhaled Drugs for Chronic Obstructive Pulmonary Disease | Health Technology Review | Therapeutic Review | Active | TR0016-000 | |||
| Adult Classical Hodgkin Lymphoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0052-000 | |||
| Federal, Provincial, and Territorial Coverage of Diagnostic Sleep Studies | Health Technology Review | Environmental Scan | Completed | ES0382-000 | |||
| pembrolizumab | Reimbursement Review | Complete | PC0343-000 | ||||
| elranatamab | Reimbursement Review | Complete | PC0315-000 | ||||
| aflibercept 8mg/0.07mL | Reimbursement Review | Complete | SR0812-000 | ||||
| Midazolam Compared With Lorazepam in Adults to Control Seizures | Health Technology Review | Rapid Review | Completed | RC1554-000 | |||
| Utilization of Long-Acting Injectable Antipsychotics | Health Technology Review | Technology Review | In Progress | HC0098-000 | |||
| Pharmaceutical Reviews Update — Issue 52 | Reimbursement Review | Pharmaceutical Review Update | |||||
| epcoritamab | Reimbursement Review | Complete | PC0334-000 | ||||
| everolimus | Reimbursement Review | Complete | SX0814-000 | ||||
| eltrombopag | Reimbursement Review | Complete | SX0777-000 | ||||
| rivaroxaban | Reimbursement Review | Complete | SX0750-000 - SR0750-000 | ||||
| nab-paclitaxel | Reimbursement Review | Complete | PX0360-000 | ||||
| Nab-paclitaxel | Reimbursement Review | Complete | PX0354-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81